Market Scenario 

Global real world evidence solutions market is projected to reach US$ 9.1 billion by 2032 from US$ 2.5 billion in 2023 by growing at a CAGR of 15.5% during the forecast period 2024 to 2032.

The demand for real-world evidence (RWE) solutions is experiencing a significant surge, driven by the need for more comprehensive data in healthcare decision-making processes. According to a study conducted in 2023, 74% of drug companies plan to invest even more in RWE solutions. Even 67% of providers have integrated this kind of data into their clinical practices so they can help patients get better. The FDA also knows about the value of using RWE in regulatory decisions – and they’re not alone: over half (55%) new drug approvals used it too! Insurers care about RWE too. In fact, 62% think its important for figuring out what should be covered and reimbursed. Not only are these benefits seen during trials but afterwards as well where costs have fallen by an average rate 45%. 

In the past, getting things from laboratories onto shelves used to take one year longer than now, which means there has been a 30% decrease in time since adopting real world evidence solutions. While recruitment is always a challenge for researchers in the real world evidence solutions market, they’ve found that using RWE can increase enrollment by as much as 40%. Right now, around 50% researchers already use them while reaching conclusions. However, this number will probably go up given another survey showed four fifths (80%) healthcare leaders believed traditional clinical trials were less representative than ones based on real world evidence. So far 60% more side effects were discovered through RWE compared with other methods – another reason why pharmaceutical industry supports this shift.

It’s clear that real world evidence solutions market is growing exponentially around the world. Wherein, 65% of RWE studies occur in countries other than the US. The most rapid growth occurs in emerging economies which saw a 70% increase in adoption, with Asia leading the way. Europe is close behind having experienced 58% more utilization rates for RWE. Additionally, technology companies have contributed significantly: among health tech start-ups surveyed worldwide, 72% were found to be working on innovations related to RWEs (real-world evidences). In the last three years alone investment into these types of ventures has gone up by 85%. This means that almost every single healthcare administrator (90%) believes that moving forward RWEs will greatly contribute towards medical knowledge. This shows just how important they are within healthcare systems today as well as tomorrow given their potential for driving change across various fields through better understanding what works where and under what conditions.

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing Demand for Personalized Medicine in Healthcare Sector

A key driver of real world evidence solutions market is greater demand for personalized medicine. By 2024, close to 78% of all healthcare providers around the world will have started utilizing RWE tools in order to provide better individualized treatment plans for their patients. The global market value of personalized medicine is estimated to hit $680 billion by 2032, growing at a CAGR of approximately 7.5%, and this will have a direct impact on RWE adoption rates as well. Additionally, two-thirds (65%) of pharma firms are now using RWDs during drug development programs designed to gain approval from regulatory agencies such as the US Food & Drug Administration; while three-quarters (73%) also employ them within clinical trials aimed at improving study design efficiency – thereby lowering costs by up to one-quarter (25%). Indeed, since real world data has been made available for use in clinical research studies, there has been seen an increase in new medications getting approved by regulatory bodies like FDA or EMA – who now approve about 30% more drugs than they did before these changes were implemented.

Besides, 80% of oncologist in the real world evidence solutions market have reported that they use RWE to make cancer treatments more personalized and this has resulted in a 35% improvement in patients’ outcomes. In developed countries, the adoption rate for electronic health records (EHRs) is now at 96%, which provides a wealth of data for RWE analysis. Healthcare spending on RWE solutions is projected to increase by an average of 15% every year with an estimated value reaching $1.2 billion by 2026. The speed at which artificial intelligence can analyze information within systems using real world evidence has been increased by 40% thereby improving the accuracy level on insights too. Additionally, 68 % of payers use RWE when deciding how much money should be reimbursed for different treatment options so as not to go beyond their budget limits while ensuring cost-effective care is provided. The demand for personalized medicine based on Real World Evidence continues rising as shown by the fact that 82 %of patients would want such kind of treatment plans tailored specifically for them alone. 

Trend: Integration of Artificial Intelligence in Real-World Evidence Solutions

Integration of artificial intelligence (AI) into real-world evidence (RWE) solutions has emerged as one of the biggest trend in real world evidence solutions market. AI-driven RWE platforms have shown a 50% increase in efficiency in processing data. This enables faster and more precise insights to be made. Around 74% of pharmaceutical companies are investing in AI to improve their capabilities with RWEs; this should grow at an average annual rate of 18% over the next few years as adoption rates increase. In 2024, two-thirds (67%) of providers offering RWE solutions will provide AI-based analytics compared with just under half (45%) last year — a significant increase. The integration has also reduced by 40% the time taken to generate actionable intelligence from this type of data. Besides, four out five health care organizations believe that artificial intelligence can dramatically enhance patients’ wellbeing through more targeted treatment recommendations.

Using AI has helped cut adverse drug events by 25% through better prediction on how patients would respond to medications, according to findings released by Health Catalyst. The global healthcare Artificial Intelligence market is expected to reach billion by 2026 and a large chunk of this investment will be directed towards supporting real world evidence generation. In addition, 78% of clinical trials in the real world evidence solutions market now incorporate AI-driven RWD for trial design optimization and patient monitoring improvements. The number of rare disease patients identified has increased by 30% due to AI-powered RWE platforms which makes it easier for researchers working on uncommon conditions find suitable subjects and treatments for them.

Moreover, 70% of health insurance firms use AI-based RWE to accelerate reimbursement and minimize expenses. Health economic outcomes research (HEOR) accuracy has grown by 35% due to RWE based on artificial intelligence, which provides more dependable information for decision-making. Furthermore, scalability of solutions based on RWD has been improved through the integration of AI, enabling examination of vast amounts of data with a 45% increase in computing speed. With recognition among medical practitioners that there are advantages associated with using AI in RWE standing at about 88%, it is clear that this upward trend will continue. It can also be seen from the fact that 92% of developers working on RWE systems consider artificial intelligence as one key component among others plans for integration into their product offerings.

Challenge: Ensuring Data Privacy and Security in Real-World Evidence

Ensuring data privacy and security remains a prominent challenge in the real world evidence solutions market. With the increasing amount of healthcare information, a staggering 78% of medical organizations have recorded data security as their top most apprehension. In 2023 alone, it is estimated that worldwide cost for health care related data breaches exceeded US$6 billion. Wherein, average data breach costed around US$10.93 million. Thus, bringing into light an urgent need for stronger measures against such attacks. Over the last two years alone, almost two-thirds (65%) of vendors dealing with RWE solutions experienced major breaches where very vital information was lost.

Furthermore, about three-quarters (72%) of patients are worried about their personal details when used in RWE studies. For this reason alone, it has become necessary to introduce advanced methods like encryption which should be applied universally by all providers so far engaged in any form of research involving patient records. These techniques are adopted by up to 85% of organizations in the global real world evidence solutions market offering these services currently. However, study suggests that only 60% of healthcare institutions have put in place comprehensive policies on data security which would protect them from various vulnerabilities thereby exposing a large group still not protected enough. It is also worth noting that while some progress has been made towards achieving better confidentiality within different sectors through use blockchain technology but there remains much work ahead since its adoption rate stands at 25%.

Segmental Analysis 

By Therapeutic Area 

With more than 32.8% market share, the oncology segment is at the forefront of real world evidence solutions market based on therapeutic area. It gives a wide-ranging view into the performance and safety of treatments beyond clinical trials’-controlled environment. This need arises because of personalized medicine which requires different patient groups data for clinical decisions making and regulatory approvals since cancer treatment are becoming more complex each day. For example, FDA has increasingly used RWE in monitoring post-market safety as well as supporting regulatory decisions thereby strengthening evidence base around new oncology therapies. In addition, global cancer burden which recorded about 19.3 million new cases in 2020 underscores the need for extensive information to enhance treatment outcomes and care given to patients. The collection of real-world data (RWD) is made possible by integrating electronic health records (EHRs), claims data and patient registries thus; this has become an integral part in oncology research and practice.

There are many reasons why real world evidence solutions market dominates in oncology. Wehrein, external control arms can be used to reduce sizes, durations or costs of trials especially when recruiting patients becomes difficult. This is especially true in cancer studies where they have to deal with many exclusion criteria’s due to comorbidity or poor prognosis. Apart from this, COVID-19 pandemic accelerated adoption of RWES through its emphasis on timely data gathering coupled with efficient analysis methods. This growth is supported by favorable regulations that support investments plus wider use EHRs among providers. This, in turn, facilitate easier way collecting required information needed during analysis stages. Additionally, biopharmaceutical companies working together with regulatory agencies played a great role towards shaping real world evidence solution market growth within innovative areas like oncology therapeutics.

By End Users

Based on end users, more than 52% of the global real world evidence solutions market share is held by pharmaceutical companies. This is because they have the ability to give holistic insights about how well a drug works, its safety features as well as usage trends in real-world settings. The shift is motivated by the need to improve decision making processes, optimize clinical trial designs and support regulatory submissions. RWE helps understand the real-world impact of therapies and devices hence FDA’s commitment towards using it for regulatory decisions shows its significance. For example, 90% of big pharma report incorporating RWE into their decision-making process. Furthermore, integration of advanced analytics and AI tools in RWE platforms enables firms to carry out extensive analysis across different patient outcomes and subpopulations thereby revealing unmet medical needs while informing strategic choices. Demand for services in real world evidence solutions market within pharmaceutical industry has been driven by massive investments on research & development activities which reached $200 billion in 2023. Thus, it is necessitating streamlined drug development processes through this method. Utilization of RWE can reduce time-to-market by up to 25% with associated costs dropping between 20-30%.

The growing emphasis on value-based care coupled with cost reduction imperatives during drug development also contributes significantly towards dominance of these solutions. The real world evidence solutions market growth is further intensified by the increased prevalence of chronic diseases as well as an aging population that demands faster healthcare interventions globally due inefficient systems hitherto available. Around 60% use RWE optimization treatment protocols within their strategies targeting management programs designed around patients suffering from chronic illnesses within modern healthcare facilities. Additionally dedicated taskforces created by bodies like EMA and FDA plus new data standards set forth them help increase adoption rates within industries

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America is currently dominating the global real world evidence solutions market due to strong healthcare infrastructure which is capable of collecting and analyzing large quantities of patient data. Furthermore, the United States has highly developed data analytics skills necessary for advanced analysis and interpretation of the collected data. The dominance of North America is also attributed to the strong presence of leading pharmaceutical and biotechnology companies. These organizations invest heavily in these products so that they can understand various aspects about real world patient outcomes, treatment effectiveness, safety profiles etcetera. Established biopharma firms in the region spend heavily on research and development, further supporting growth within this industry. Additionally, availability financial resources coupled with technological knowhow boosts adoption rates for RWE solutions within North America.

Moreover, there are certain factors that make North America enjoy more favorable regulation compared to other regions around the world real world evidence solutions market. For instance, the US FDA plays an important role by encouraging integration clinical decisions making processes through their guideline’s frameworks on usage RWEs during drug development. This was achieved mainly because of strategic framework which was put place back in 2019 by Food Drug Administration [FDA]. Such kind regulatory backing breeds confidence among stakeholders like insurers pharmaceutical companies and healthcare providers among others. Thereby, it is driving up demands for real world evidence solutions within North America.

Top Companies in Global Real World Evidence Solutions Market

• SAS
• Syneos Health
• IBM
• Anthem
• Clinigen Group
• Palantir Technologies
• Flatiron Health
• IQVIA
• ICON
• PAREXEL
• Optum
• Cognizant
• Oracle
• Clarivate plc
• Medpace Holding Corporation
• Elevance Health Inc
• Other Prominent Players

Market Segmentation Overview:

By Therapeutic area

• Cardiovascular Oncology
• Immunology
• Others

By Component

• Dataset
• Services

By End User

• Medical Devices
• Pharmaceutical
• Payers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America